Prognostic Impact of NANOG Immunohistochemical Expression in Endometrial Carcinoma: Clinicopathological Study | ||
| Zagazig University Medical Journal | ||
| Articles in Press, Accepted Manuscript, Available Online from 12 April 2025 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/zumj.2025.371714.3893 | ||
| Authors | ||
| Mahmoud Wahied Emara1; Hanaa M. Ibrahim2; Aya G. Mohamed Sarhan* 3; Doaa I. Abdelrahman2 | ||
| 1Professor of Pathology department, Faculty of Medicine, Zagazig University, Egypt | ||
| 2Assistant Professor of Pathology department, Faculty of Medicine, Zagazig University, Egypt | ||
| 3Pathology Department, Faculty of Medicine, Zagazig University, Egypt | ||
| Abstract | ||
| Background: Endometrial cancer (EC) stem cells play an important role in the development of endometrial cancer and they are responsible for tumor progression, invasiveness, metastasis and drug resistance. NANOG has been found to be surrogate indicators for cancer stem cells (CSCs). Therefore, in order to improve endometrial carcinoma management, we set out to assess the immunohistochemical expression of the cancer stem cell marker NANOG in endometrial carcinoma and their correlation with several clinicopathological features. Methods: This cohort study was conducted in the Pathology department, included tissue samples from 31 patients diagnosed with endometrial carcinoma, admitted and underwent hysterectomy at the obstetrics and gynecology department of Zagazig University, who have undergone hysterectomy to treat endometrial carcinoma. All study subjects were subjected to accurate and complete patient clinicopathological data from archives. Testicular seminoma was taken as a positive control to assess the expression of NANOG. NANOG expression is considered positive if nuclear staining was present in glandular epithelium of endometrium. Results: There was a statistically significant association between NANOG expression and clinicopathological characteristics among the studied group, as high NANOG expression was associated with high FIGO grade, high FIGO stage, and TNM stage (P=0.02), (P=0.005) and (P=0.005) respectively. Furthermore, there was no significant association between NANOG expression and tumor size (p=0.86). Conclusion: EC expressing high NANOG are highly aggressive tumors, therefore it could be promising therapeutic targets for EC as NANOG is highly expressed in most CSCs, NANOG is a desirable target for cancer therapy which could improve human health | ||
| Keywords | ||
| Endometrial carcinoma; immunohistochemical expression; Cancer stem cells; NANOG | ||
|
Statistics Article View: 31 |
||
